SHIFT Newsroom · GLOBAL
Heart failure and obesity: separate evidence for two drug classes
This review discusses tirzepatide and SGLT2 inhibitors in heart failure with preserved ejection fraction and obesity. Evidence from separate treatments or trials does not establish that a combined regimen was tested or is suitable for an individual patient.
What the source says
This review discusses tirzepatide and SGLT2 inhibitors in heart failure with preserved ejection fraction and obesity. Evidence from separate treatments or trials does not establish that a combined regimen was tested or is suitable for an individual patient.
Evidence and limits
The authors synthesise separate trial and mechanistic evidence. They state that differences between trial populations prevent a valid direct comparison and that the combination has not been tested in a dedicated randomised trial. Complementary mechanisms do not establish the safety or benefit of combining medicines.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
A person with heart failure needs advice from their treating team. This review does not establish a combined regimen or support an independent medicine change.
Known facts
- This review discusses tirzepatide and SGLT2 inhibitors in heart failure with preserved ejection fraction and obesity.